HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Randomized, double-blind, placebo-controlled international clinical trial of the Ampakine CX516 in elderly participants with mild cognitive impairment: a progress report.

Abstract
This progress report briefly describes the rationale and study design for the first cross-national clinical study of a positive AMPA-type glutamate receptor modulator in subjects with mild cognitive impairment (MCI). The study medication for the double-blind, placebo-controlled trial, the AMPAKINE CX516, represents a novel pharmacological approach to the treatment of memory disorders. Previous preclinical and pilot clinical studies have shown that CX516 has the ability to enhance memory and cognition. Design of the trial, including outcome measures and inclusion criteria, was aided by an international panel of experts in the newly emerging field of MCI.
AuthorsSteven A Johnson, Vincent F Simmon
JournalJournal of molecular neuroscience : MN (J Mol Neurosci) 2002 Aug-Oct Vol. 19 Issue 1-2 Pg. 197-200 ISSN: 0895-8696 [Print] United States
PMID12212780 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • 1-(quinoxalin-6-ylcarbonyl)piperidine
  • Dioxoles
  • Excitatory Amino Acid Agonists
  • Piperidines
  • Receptors, AMPA
Topics
  • Aged
  • Cognition Disorders (drug therapy, metabolism)
  • Dioxoles (pharmacology, therapeutic use)
  • Double-Blind Method
  • Excitatory Amino Acid Agonists (pharmacology, therapeutic use)
  • Female
  • Humans
  • Male
  • Memory Disorders (drug therapy, metabolism)
  • Middle Aged
  • Piperidines (pharmacology, therapeutic use)
  • Receptors, AMPA (drug effects, metabolism)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: